{
  "content": "Diagnosis:\t\tGastric adenocarcinoma, intestinal type\n\nManagement:\t\tTotal gastrectomy 15 Jan 2024\n\t\tAdjuvant CAPOX-Trastuzumab completed March 2024\n\nHistology:\t\tpT2N0M0, HER2 positive (3+)\n\nCurrent Situation:\tFirst surveillance review\n\n[redacted name] attended clinic today for first surveillance review following completion of adjuvant chemotherapy. She has recovered well from her treatment with good energy levels and is now back at work part-time. Her weight has stabilized at 62kg and she is managing a normal diet with small frequent meals as advised by the dietitian. No concerning symptoms reported. Blood tests show stable parameters with normal tumour markers. The plan is to continue 3-monthly Trastuzumab until January 2025 and arrange surveillance CT in 3 months' time. We will review her again following the scan.",
  "output": {
    "primary_cancer": {
      "site": "gastric",
      "year": 2024,
      "month": 1,
      "metastases": null,
      "tnm_stage": "pT2N0M0",
      "other_stage": null,
      "histopathology_status": "intestinal type adenocarcinoma",
      "biomarker_status": "HER2 positive (3+)",
      "cancer_timeline": [
        {
          "type": "treatment_surgery",
          "value": "Total gastrectomy",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_start",
          "value": "Commenced adjuvant CAPOX-Trastuzumab",
          "year": 2024,
          "month": 1
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed CAPOX component of adjuvant therapy",
          "year": 2024,
          "month": 3
        },
        {
          "type": "laboratory_finding",
          "value": "Normal tumour markers",
          "year": 2024,
          "month": 4
        }
      ]
    },
    "other_cancers": [],
    "patient_facts": [
      {
        "type": "quality_of_life_finding",
        "value": "Back at work part-time"
      },
      {
        "type": "investigation_finding",
        "value": "Blood tests show stable parameters with normal tumour markers"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "First surveillance review following completed adjuvant CAPOX-Trastuzumab for early stage gastric cancer. Good recovery from treatment with stable weight and normal diet tolerance."
      },
      {
        "type": "update_to_treatment",
        "value": "Continuing 3-monthly Trastuzumab until January 2025"
      },
      {
        "type": "planned_investigation",
        "value": "Surveillance CT in 3 months"
      },
      {
        "type": "follow_up_referral",
        "value": "Review following CT scan"
      }
    ]
  }
}